Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

Haematoma expansion affects a fifth of patients within 24 h of the onset of acute
intracerebral haemorrhage and is associated with death and disability, which makes it an …

Background Patients with acute intracerebral hemorrhage who are receiving factor Xa
inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that …

Purpose—The aim of this guideline is to present current and comprehensive
recommendations for the diagnosis and treatment of spontaneous intracerebral …

Background and Purpose—The aim of the study was to investigate the usefulness of the
computed tomography (CT) island sign for predicting early hematoma growth and poor …

Background and Purpose—Early hematoma growth is not uncommon in patients with
intracerebral hemorrhage and is an independent predictor of poor functional outcome. The …

Importance Many clinical trials focus on restricting hematoma expansion following acute
intracerebral hemorrhage (ICH), but selecting those patients at highest risk of hematoma …

Background Despite intracerebral haemorrhage causing 5% of deaths worldwide, few
evidence-based therapeutic strategies other than stroke unit care exist. Tranexamic acid …

Non-traumatic intracerebral hemorrhage (ICH) is associated with a significant global burden
of disease, and despite being proportionally less frequent than ischemic stroke, in 2010 it …

Intracerebral hemorrhage (ICH), the most devastating form of stroke, has no specific therapy
proven to improve outcome by randomized controlled trial. Location and baseline hematoma …